Phase I-II Study of Trabectedin Combined With Radiotherapy to Treat Soft Tissue Sarcoma Including Liposarcoma and Leiomyosarcoma
Led by Grupo Espanol de Investigacion en Sarcomas · Updated on 2023-05-31
199
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the combination of trabectedin and radiotherapy to reduce tumors in patients with various types of soft tissue sarcoma. This Phase I-II trial evaluates different doses of trabectedin alongside specified radiation doses to measure tumor shrinkage and survival outcomes. The study includes four patient groups based on sarcoma type and tumor location, with cohorts A and B closed to new participants since 2023.
The treatment involves intravenous trabectedin given over 24 hours every three weeks at doses of 1.3 or 1.5 mgm2, combined with radiotherapy delivered in fractions ranging from 30 Gy to 45 Gy depending on the patient cohort. Cohort A patients may receive unlimited chemotherapy cycles, while cohorts B and C receive three cycles. Radiotherapy schedules vary by group, and a translational substudy examines biomarkers to predict treatment response.
Participants undergo regular tumor imaging with CT and MRI scans, clinical evaluations, and quality of life questionnaires over months to years. Tumor responses are assessed every 6 weeks or 4 months depending on cohort, and safety is monitored through adverse event tracking every 21 days. Survival and relapse outcomes are followed for up to five years. Centralized pathology and radiology reviews support treatment decisions, and all participants must have a central venous catheter for chemotherapy delivery.
CONDITIONS
Brief Title
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Research Team
A
Adriana Rojo
E
Elisa Cerezo, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with specific types of soft tissue sarcoma as defined per cohort
Tumor must be resectable or limited to lung metastases depending on the cohort
Disease distribution allows safe radiation therapy as confirmed by radiation oncologist
Measurable disease according to RECIST or Choi criteria
Performance status ECOG 0-1
Adequate respiratory, bone marrow, liver, kidney, and cardiac function
Negative pregnancy test and use of effective contraception if of childbearing potential
Central venous catheter for treatment
No prior trabectedin treatment
No uncontrolled infections or significant systemic diseases
Signed informed consent before study procedures
You will not qualify if you...
Prior treatment with trabectedin or radiotherapy that conflicts with study protocol
Performance status ECOG 2 or higher
Elevated bilirubin or creatinine beyond specified limits
History of other cancer within 5 years (except certain treated cases)
Severe pulmonary or cardiovascular disease
Uncontrolled infections including HIV
Pregnant or breastfeeding women
Participation in another clinical trial or investigational treatment within 30 days
Psychological or social circumstances limiting compliance
Tumors unresectable or not fitting cohort-specific criteria
Presence of metastases beyond allowed sites or lymph node involvement
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 9 weeks for 3 cycles or longer for unlimited cycles depending on cohort
Participants receive trabectedin chemotherapy via 24-hour intravenous infusion every 3 weeks combined with radiotherapy. Radiotherapy doses vary by cohort, ranging from 30Gy in 10 fractions to 45Gy in 25 fractions.
Weekly visits for treatment and assessments during active therapy
Follow-up
Duration - Up to 24 months with extended survival follow-up up to 5 years
Participants are monitored for tumor response, adverse events, survival, and quality of life after treatment completion.
Visits every 3 months for up to 24 months and periodic assessments up to 5 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Phase 1 Study of Abemaciclib with Radiation Therapy Before Surgery for High-Risk Adipocytic Retroperitoneal Sarcomas
Phase 1 Study Evaluating OKN4395 Alone or with Pembrolizumab in Adults with Advanced Solid Tumors
Phase 1b Open-Label Trial of Oral REC-617 for Adults with Metastatic or Unresectable RB1-Negative Leiomyosarcoma After Previous Treatment
Ivonescimab Treatment for Advanced or Unresectable Leiomyosarcoma Previously Treated
Phase II Clinical Trial Evaluating Safety and Effectiveness
Study of Mirdametinib with Palbociclib for Advanced Dedifferentiated Liposarcoma Treatment
Study of APG-115 Combined With Toripalimab for Treating Advanced Liposarcoma or Other Advanced Solid Tumors
Phase IbII Drug Trial to Find Safe Dose and Test Effectiveness
Understanding Beliefs and Attitudes About Genetic Testing in Adults with Leiomyosarcoma and Their Family Members
Study of Colon and Rectal Surgery Techniques and Quality of Life in Adults With Retroperitoneal Sarcoma
Study of Walking Difficulties in Children and Teens After Orthopedic Surgery for Cancer-Related Conditions Compared to Healthy Peers
PROSARC-2 Phase II Trial of Dose-Escalated Proton Radiotherapy for Inoperable Soft Tissue Sarcoma
Multicenter Study Assessing Tumor Control and Biomarkers
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.
Javier Martin-Broto, Nadia Hindi, Antonio Lopez-Pousa...